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Abstract
Background: The biological potential of prostate cancer is extremely variable. Particular interest
is focused on markers not expressed in normal prostatic tissues. pS2 protein expression has been
demonstrated in a range of malignant tissues in an oestrogen-independent pathway. Recently, it has
been demonstrated that pS2, in prostate cancer, is closely associated with neuro-endocrine
differentiation. In the present study, we have analyzed, the potential of Neuro-endocrine and pS2
(TFF1) expression in human prostate cancer determined by immunohistochemistry, in primary
adenocarcinoma of the prostate and attempted to correlate this with the clinico-pathologic
features of the patient and neuroendocrine expression.
Methods: Ninety-five malignant prostatic specimens from primary adenocarcinoma, obtained
from either transurethral resection of prostate or radical retropubic prostatectomy, from 84
patients between January 1991 and December 1998 were evaluated by immuno-histochemical
staining using selected neuroendocrine tumor markers i.e. chromogranin A (CgA) and estrogen
inducible pS2 protein. The relationship between the expressions of pS2 was studied with CgA
expression, clinical stage (TNM) and tumour grade (Gleason system). Fischer exact test was used
for statistical analysis.
Results: The mean age of the patients was 70 + /- 9.2 years. The pS2 expression was seen in 10%
of primary prostate cancers. Worsening histological grade was associated with greater expression
of pS2 (p < 0.001). The expression of CgA was noted in 31% of malignant prostatic tissue. In pS2,
positive cases 2/3rd of patients were also CgA +ve. However, there was no significant correlation
between pS2 expression and the stage of disease.
Conclusion: pS2 expression in prostate cancer significantly correlates with histological grade and
the neuroendocrine differentiation, as demonstrated by Chromogranin A expression but not with
the clinical stage of the disease. However, the overall expression was low consequently; no
definitive conclusions can be drawn. We feel further work is required in a larger series, both in
primary and metastatic cancer.
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Background
The biological potential of prostate cancer is extremely
variable [1]. It is perhaps the only cancer, which could be
managed by, deferred treatment in its early course for
selected cancers [2]. To define the biological potential of
prostate cancer, prognostic markers are employed. There
are numerous markers for assessing the biological aggres-
siveness of the prostate cancer [3]. However, large studies
have shown that they lack sensitivity and specificity due
primarily to their expression in normal prostatic epithe-
lium as well. This justifies a recent surge in interest in
markers specific to malignant prostatic tissue [4]. Recent
studies have shown the potential of neuro-endocrine dif-
ferentiation in adenocarcinoma of the prostate and its
role in ascertaining the biological aggressiveness of the
tumor [3]. Wang et al [5] has recently noted that the
expression of the pS2 protein is implicated in the patho-
genesis and progression of some neuro-endocrine tumors.
Maisakowski et al. first described the pS2 gene in the
MCF-7 human breast cancer cell line [6]. The pS2 is a
cysteine rich secretory protein, containing 84 amino acids
and a molecular weight of 6.45 k-Da. The pS2 gene is
highly expressed in estrogen-receptor positive breast can-
cer, and high levels of pS2 protein correlate with respon-
siveness to primary endocrine therapy and better patient
survival in breast cancer. However, in prostate cancer it is
linked with NE differentiation and poorer outcome [7].
In the present study, we have investigated the expression
of pS2 in malignant primary prostatic tissue in specimens
obtained from transurethral, open prostatectomy, and
correlated this with neuro-endocrine differentiation and
clinical stage and grade. This is a preliminary report on
pS2 expression in prostate cancer, a larger study will better
define the correlation between stage, grade of cancer with
pS2 and CgA expression.
Methods
Demographic profile
Ninety-five malignant consecutive primary prostatic spec-
imens were obtained from 84 patients by either trans-ure-
thral resection of prostate (n = 69 patients) for urinary
obstruction or from radical retro-pubic prostatectomy (n
= 15 patients) between January 1991 and December 1998.
These tissue specimens were taken from the archived
records of the department of pathology. The age ranged
from 52–93 years (mean 70 + 9.2 years).
Immuno-histochemical staining for pS2 and Chrom-
ogranin A Sections were stained for H & E as well as for
pS2 (Novocastra, UK Cat. # NCL-pS2) and Chromogranin
A (DAKO, Glostrup, Denmark Cat # A0430) by immuno-
histochemistry using indirect immunoperoxidase
technique.
Briefly, 3 µm thick tissue sections were cut and mounted
on poly-L-lysine (sigma) coated slides. Sections were
deparaffinized in xylene and re-hydrated through graded
alcohol series followed by water. Antigen retrieval was
done in case of pS2 with 10 mM citrate buffer, 6.0 in a
microwave oven 3 × 5 seconds at 450 W, then gradually
cooled down to room temperature.
Sections were washed with water followed by Phosphate
buffer saline (PBS) rinse.
Endogenous peroxidase in the sections was blocked for 30
minutes with 0.3% H2 02 in methanol. Sections were
washed with PBS. All sections were treated with Normal
Swine serum (NSS) prediluted 1:10 in PBS for 5 minutes.
The sections were then incubated with the primary anti-
body to pS2 diluted with NSS (1:100) and Chromogranin
A (1:20) for 90 minutes at room temperature. Slides were
washed with PBS and incubated with peroxidase-conju-
gated swine anti rabbit secondary antibody (DAKO) at a
dilution of 1:150 for 45 minutes at room temperature. 3,
3'-diaminobenzidine (DAB) was used as a final Chro-
mogen. Harris Haemtoxylin was used as a counter nuclear
stain. Positive and negative controls were used with all
batches of IHC staining. A prostatic adenocarcinoma spec-
imen section expressing pS2 was used as a positive con-
trol. Same case exhibiting the primary antibody was used
a negative control with each staining procedure. The
extent of pS2 reactivity was semi quantitatively assessed
by estimating the percentage of positive acini present in
the whole mounted sessions. Expression was graded ++ if
more than 50% of the tissue showed expression, + if
between 5 and 49% showed expression and focal if <5%
showed expression.
Histological grading The Gleason system was used for
grading of the cancer specimens; a senior histopathologist
(SP) blinded of previous Gleason grading and clinical
course did this. Based upon the Gleason score patients
were divided into three groups i.e. well differentiated
(Gleason sum 2–4), moderately differentiated (Gleason
sum 5–7) and poorly differentiated (Gleason sum 8–10).
To study correlation and determine the p value Student t
test was applied.
Results
The cancerous lesion composed of 35% (n = 29) stage T1,
32% (n = 27) stage T2, 25% (n = 21) stage T3 and 6% (n
= 5) stage T4 disease according to the TNM classification.
Based upon the stage of the disease patients were divided
into three groups i.e. organ confined (T1-2), locally inva-
sive (T3-4 and N1) and metastatic (M1) cancer.BMC Urology 2004, 4:14 http://www.biomedcentral.com/1471-2490/4/14
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In 95-cancer specimen from transurethral resection (n =
69) for urinary obstruction and radical retropubic prosta-
tectomy for organ-confined cancers (n = 15), pS2 reactiv-
ity was detected in the adjoining normal or hyperplastic
acini in only 4.2%. The pS2 expression in cancer was
found in 10% (figure 1). The immuno-histochemical
reactivity of pS2 in malignant epithelial cells was confined
to the cytoplasm of with a tendency to a perinuclear
accentuation.
Expression of pS2 was correlated with the stage of disease
in Figure 1. Staining for NE marker (CgA) was seen in 31%
(figure 1); correlation between the pS2 and CgA expres-
sion is summarized in table 1, it showed that 2/3rd of pS2
also showed CgA expression.
Worsening histological grade was associated with greater
expression of pS2. In Gleason sum groups 2–4 and 5–6,
expression of pS2 was noted in 6 and 8% respectively
whereas in Gleason sum group 8–10 the expression was
observed in 30% (p < 0.001). The expression of pS2 [fig-
ure 4(a) and 4(b)] in various prognostically and therapeu-
tically distinct groups based upon the grade of cancer is
described in figure 2.
Discussion
In the present study, we investigated the expression of pS2
protein in the adenocarcinoma of prostate and in the sur-
rounding normal prostate tissue. We used a standard
immunohistochemical method to assess pS2 expression
in tissue sections of adenocarcinoma prostate instead of
instead of biochemical or immuno-radiometric assay. The
immuno-histochemical method for detection of pS2
expression has drawbacks in comparison to biochemical
and immunoradiometric assay on tissue extracts. Both of
Expression of pS2 % in organ confined, locally advanced  (locoregional) and metastatic adenocarcinoma of the  prostate Figure 1
Expression of pS2 % in organ confined, locally advanced 
(locoregional) and metastatic adenocarcinoma of the 
prostate.
Correlation of Gleason sum and pS2 expression Figure 2
Correlation of Gleason sum and pS2 expression.
Photomicrograph of prostatic adenocarcinoma stailed with a  polyclonal against pS2 Figure 4
Photomicrograph of prostatic adenocarcinoma stailed with a 
polyclonal against pS2. Note prominent perinuclear brown 
staining in tumour cells. Magnification: 40×
Table 1: Correlation of pS2 expression with CgA expression and 
Gleason sum (GS)
n (%) CgA +ve CgA -ve Mean GS
pS2 +ve. 9(10) 67% 33% 7.5
pS2 -ve. 86(90) 28% 72% 6.2
+ve. Expression positive
-ve. Expression negative
CgA Chromogranin A
GS Gleeson sumBMC Urology 2004, 4:14 http://www.biomedcentral.com/1471-2490/4/14
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the later methods allow precise quantification of levels of
expression for a better correlation with other parameters
studied.
However, as we are interested in the clinical utility of pS2
expression in our prostate cancer population, we used
immunohistochemistry, which allows appreciation of
intra-tumoral heterogeneity of expression and of both
cancerous and non-cancerous cells. pS2 protein expres-
sion has been demonstrated in a range of malignant and
benign pathologies. It is highly expressed in receptor pos-
itive human breast cancer [5] but expression in other can-
cers like ovarian [7], cervical [8], gastrointestinal [9],
thyroid [10] and bladder [11] is variable.
A significant implication of pS2 in prostate cancer is the
close association of this marker with Neuroendocrine
(NE) differentiation. There is increasing evidence that
focal NE differentiation frequently occurs in prostatic
adenocarcinoma and it may have significant prognostic
implications [12-14]. NE differentiation is also described
in hormone refractory prostate cancer; Krijnen et al [14]
noted that androgen receptors are not present in prostatic
adenocarcinoma staining positive for CgA. While Higash-
iyama noted 17% expression of pS2 in all pulmonary can-
cers, Wang et al [5] noted 45% expression in small cell
cancers of the lung (a neuroendocrine carcinoma). Recent
evidence has suggested that expression of pS2 is closely
associated with neuroendocrine differentiation in pros-
tate cancer [15]. Colombel et al from in an RT-PCR study
found a high expression of pS2 in prostate cancer; how-
ever, they found no correlation between with tumour
stage or Gleason grade. Our present work [15] indicates
that NE differentiation not only correlates with other
prognostic markers like grade of the cancer but also has
independent prognostic value. Bonkhoff et al [15] noted
that pS2 expression was consistently confined to NE dif-
ferentiation in untreated tumors and in carcinomas that
relapsed after hormonal therapy. Our results have simi-
larly shown that 6 out of 9 cancers that have expressed pS2
were also positive for CgA.
Conclusions
Our results demonstrate that although the expression of
pS2 protein was noted in only 1/10th of prostate cancers,
it significantly correlates with the histological grade and
NE differentiation; both have independent and interde-
pendent prognostic value. There is dearth of data explor-
ing the correlation of pS2 expression and aggressiveness of
prostate cancer cell behavior. Limited literature available
at present show significant association of pS2 expression
with prognosis in prostate cancer, however more work is
required to explore the utility of this marker in defining
the biological potential of prostate cancer.
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